tbuckley/cabot-search huggingface dataset:
Supplemental Feedings for High-Risk Preterm Infants
Authors: Arthur I. Eidelman
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the Cmwp of the EBMT
Authors: Marie Robin, Porcher Raphael, Anja van Biezen, Liisa Volin, Ghulam J. Mufti, Charles Craddock, Jurgen Finke, Carlos Richard Espiga, Jakob Passweg, Andrew Peniket, Johan Maertens, Gulsan Sucak, Tobias Gedde-Dahl, Antonin Vitek, Arnon Nagler, Didier Blaise, Dietrich Beelen, Natacha Maillard, Rainer Schwerdtfeger, Simona Iacobelli, Theo de Witte, Nicolaus Kroeger
Journal: Blood (2014)
Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial.
Authors: Michel Delforge, Leonard Minuk, Jean-Claude Eisenmann, Bertrand Arnulf, Letizia Canepa, Alberto Fragasso, Serge Leyvraz, Christian Langer, Yousef Ezaydi, Dan T. Vogl, Pilar Giraldo-Castellano, Sung-Soo Yoon, Angelo Martins, Charles Zarnitsky, Martine Escoffre Barbe, Bernard Lemieux, Irina Proskorovsky, Annette L. Ervin-Haynes, Vanessa Houck, Thierry Facon
Journal: Journal of Clinical Oncology (2014)

8516^ Background: In the pivotal FIRST trial, continuous lenalidomide plus low-dose dexamethasone (Rd; [N = 535]) improved progression-free survival (PFS) and overall survival (OS) compared with 18 cycles of Rd (Rd 18; [N = 541] for and 12 cycles of melphalan-prednisone-thalidomide (MPT; [N = 547] for 72 weeks) (Facon, Blood 2013). This analysis evaluates HRQOL changes in these NDMM pts. Methods: HRQOL was assessed using the EORTC-QLQ-C30, QLQ-MY20, and EQ-5D validated questionnaires at baseline, end of cycle 1, then 3, 6, 12, 18 months (mos), and at study discontinuation. Cross sectional and longitudinal analyses were performed. Changes from baseline at each time-point were estimated with a focus on seven pre-selected and clinically-relevant domains (Global QOL, Physical Functioning, Pain, Fatigue, Disease Symptoms, Side Effects of Treatment, and Health Utility). Results: Questionnaire compliance was high (≥ 84%) at Cycle 1, 3 and 6 mos across treatment arms. At 12 and 18 mos, the compliance rates were lower in the MPT arm than the Rd arms, 81% vs. 91% and 67% vs. 89% respectively (P ≤ 0.002). Statistically significant (P ≤ 0.05) improvement from baseline in HRQOL scores was observed in all treatment arms, in 6 out of the 7 domains at most time-points. For the Side Effects domain, treatment with MPT showed a consistent and significant worsening from baseline at all the assessments. In addition Side Effects for MPT had a significantly worse score than continuous Rd at Cycle 1, 3 and 12 mos (P ≤ 0.05). Progressive disease (PD) was associated with worsening in HRQOL scores for all domains across all 3 treatment groups (P < 0.001). Conclusions: In NDMM transplant ineligible pts, continuous Rd treatment resulted in improved PFS and OS thus improving clinically relevant HRQOL measurements over the course of treatment and better QOL related to treatment side effects than MPT. HRQOL improved with treatment and was generally maintained while subjects were progression-free. PD was associated with worsening HRQOL across evaluated domains. MPT therapy was perceived as having worse Treatment Side Effects as compared to Rd. Clinical trial information: 00689936.
Comparison of Prognostic Scoring Systems for Prediction of Survival in Hepatocellular Carcinoma
Authors: B. Baran, O. Ekinci, O.M. Soyer, A.C. Ormeci, S. Gokturk, S. Evirgen, A. Poyanli, M. Gulluoglu, F. Akyuz, C. Karaca, K. Demir, F. Besisik, S. Kaymakoglu
Journal: Journal of Hepatology (2016)
Efficacy and Safety Of Treatments For Relapsed Or Refractory Mantle Cell Lymphoma (MCL): Results Of a Systematic Literature Review
Authors: Annete Njue, Peter C Trask, Ann Colosia, Robert Olivares, Shahnaz Khan, Adeline Abbe, Rachel Lee Police, Jianmin Wang, Elizabeth Sherrill, James A. Kaye, Farrukh T Awan
Journal: Blood (2013)
Molecularly imprinted nanoparticles and their releasing properties, bio-distribution as drug carriers
Authors: Yongyan Zhu, Ling Yang, Dandan Huang, Quanhong Zhu
Journal: Asian Journal of Pharmaceutical Sciences (2016)

Molecular imprinted nanoparticles (MINPs) can memorize the shape and functional group positions complementary to template, which account for the large drug loading capacity and slow drug release behavior as drug carriers. We synthesized MINPs via precipitation polymerization with vinblastine (VBL) as a model drug, and investigated the drug loading, releasing property in vitro and bio-distribution in vivo. The obtained MINPs, from 300 to 450 nm, had smooth surface and favorable dispersibility. The entrapment efficacy and drug loading capacity of VBL loaded MINPs (MINPs-VBL) were 83.25% and 8.72% respectively. In PBS (pH7.4), MINPs-VBL showed sustained release behavior. The cumulative release percentage reached about 70% during 216 h and no burst release was observed. The releasing behavior of MINPs-VBL in vitro conformed to the first-order kinetics model. MINPs-VBL and commercially available vinblastine sulfate injection (VBL injection) were injected via tail vein of SD rats respectively to investigate the bio-distribution. MINPs-VBL group showed higher concentration of VBL in tissues and serum than VBL injection group after 60 min, and the drug level in liver was the highest. MINPs-VBL exhibited liver targeting trend to some extent, which was based on the evaluation of drug targeting index (DTI) and drug selecting index (DSI).
P0621 : Hepatitis E virus in patients with decompensated chronic liver disease and alcoholic hepatitis: A UK/French study
Authors: R.G. Madden, H. Blasco-Perrin, A. Stanley, C. Crossan, J.G. Hunter, L. Vine, K. Lane, N. Devooght-Johnson, C. Mclaughlin, J. Petrik, B. Stableforth, H. Hussaini, M. Phillips, J.M. Mansuy, E. Forrest, J. Izopet, O. Blatchford, L. Scobie, J.M. Peron, H.R. Dalton
Journal: Journal of Hepatology (2015)
High Blast Percentage, Chromosome 17 Abnormalities and Severe Pancytopenia Predict Death within Twelve Months in Patients with Myelofibrosis.
Authors: Constantine S. Tam, Jorge Cortes, Alice Lynn, Lynne V. Abruzzo, Deborah A. Thomas, Sherry Pierce, Lingsha Zhou, Michael J. Keating, Hagop Kantarjian, Srdan Verstovsek
Journal: Blood (2007)
Simultaneous Haploidentically Mismatched Stem Cell Transplantation from Multi-Donors (MDT) in Humans Offers Better Engraftment as Compared to Single Haploidentical Donor.
Authors: Michael Y. Shapira, Igor B. Resnick, Benjamin Gesundeheidt, Simcha Samuel, Liliane Drey, Yuri Verkholevsky, Shimon Slavin, Reuven Or
Journal: Blood (2007)
The Hypoxic Response and Altered Gene Expression in Patients with Sickle Cell Disease
Authors: Victor R. Gordeuk, Xu Zhang, Wei Zhang, Shwu-Fan Ma, Galina Miasniakova, Adelina Sergueeva, Tatiana Ammosova, Min Xu, Sergei Nekhai, Josef T. Prchal, Michael Wade, Joe GN Garcia, Roberto Machado
Journal: Blood (2012)
Gut-Liver Axis in Cystic Fibrosis: Lack of Association between Intestinal Inflammation and Liver Disease in Adult Cystic Fibrosis Patients after Lung Transplantation
Authors: E. Halilbasic, K. Staufer, D. Schmidt, S. Schick, A. Brichta, P. Jaksch, W. Klepetko, H. Vogelsang, M. Trauner, L. Kazemi-Shirazi
Journal: Journal of Hepatology (2016)
Age-Associated Sirtuin 1 Reduction in Vascular Smooth Muscle Links Vascular Senescence and Inflammation to Abdominal Aortic Aneurysm
Authors: Hou-Zao Chen, Fang Wang, Peng Gao, Jian-Fei Pei, Yue Liu, Ting-Ting Xu, Xiaoqiang Tang, Wen-Yan Fu, Jie Lu, Yun-Fei Yan, Xiao-Man Wang, Lei Han, Zhu-Qin Zhang, Ran Zhang, Ming-Hui Zou, De-Pei Liu
Journal: Circulation Research (2016)

Uncontrolled growth of abdominal aortic aneurysms (AAAs) is a life-threatening vascular disease without an effective pharmaceutical treatment. AAA incidence dramatically increases with advancing age in men. However, the molecular mechanisms by which aging predisposes individuals to AAAs remain unknown.In this study, we investigated the role of SIRT1 (Sirtuin 1), a class III histone deacetylase, in AAA formation and the underlying mechanisms linking vascular senescence and inflammation.The expression and activity of SIRT1 were significantly decreased in human AAA samples. SIRT1 in vascular smooth muscle cells was remarkably downregulated in the suprarenal aortas of aged mice, in which AAAs induced by angiotensin II infusion were significantly elevated. Moreover, vascular smooth muscle cell-specific knockout of SIRT1 accelerated angiotensin II-induced formation and rupture of AAAs and AAA-related pathological changes, whereas vascular smooth muscle cell-specific overexpression of SIRT1 suppressed angiotensin II-induced AAA formation and progression in Apoe-/- mice. Furthermore, the inhibitory effect of SIRT1 on AAA formation was also proved in a calcium chloride (CaCl2)-induced AAA model. Mechanistically, the reduction of SIRT1 was shown to increase vascular cell senescence and upregulate p21 expression, as well as enhance vascular inflammation. Notably, inhibition of p21-dependent vascular cell senescence by SIRT1 blocked angiotensin II-induced nuclear factor-κB binding on the promoter of monocyte chemoattractant protein-1 and inhibited its expression.These findings provide evidence that SIRT1 reduction links vascular senescence and inflammation to AAAs and that SIRT1 in vascular smooth muscle cells provides a therapeutic target for the prevention of AAA formation.
Clinical relevance of plasma matrix metalloproteinase-2 levels in primary invasive breast cancer
Authors: J. Decock, H. Wildiers, M.-R. Christiaens, P. Neven, R. Paridaens
Journal: Journal of Clinical Oncology (2005)

9680 Background: Matrix metalloproteinases (MMPs) belong to a family of enzymes involved in degradation of the extracellular matrix, a key event in tumor progression, invasion and metastasis. Upregulated expression of MMPs is observed in tumor tissue of different cancers and high levels were found in serum and plasma of many cancer patients. The 2 gelatinolytic MMPs, MMP-2 and MMP-9 specifically degrade the basement membrane and may be the most important MMPs in tumor progression. Methods: We therefore studied the correlation between plasma MMP-2 levels of patients with newly diagnosed invasive breast cancer and several clinicopathological factors. We developed a MMP-2 Enzyme-Linked immunoassay on the Gyros Bioaffy system, using only very low amounts of plasma, i.e. 400 nanoliter per data point. After optimalisation and validation, this MMP-2 immunoassay was used to study plasma samples taken at time of diagnosis in 69 breast cancer patients before any treatment. Results: Using non parametric statistics, no significant correlation was found between plasma MMP-2 levels and the main clinicopathological factors such as pathological tumor size (p=0,72), lymph node involvement, (p=0,59), hormone receptor status (p=0,90) and differentiation grade (p=0,67). Plasma MMP-2 levels didn’t differ significantly between the 17 patients with invasive lobular carcinoma and the 47 patients with invasive ductular carcinoma (p=0,36). The plasma MMP-2 levels didn’t differ significantly between patients with Her-2 negative and Her-2 strong positive expression (p=0,58). These results were confirmed by a commercial sELISA. Conclusions: Plasma MMP-2 levels in primary invasive breast cancers aren’t significantly related with pathological tumor size, lymph node involvement, hormone receptor status, differentiation grade, histopathological type or Her-2 expression. This work was supported by a grant from the EU, “Cancerdegradome”, contract no. 503297. No significant financial relationships to disclose.
Cytotoxicity Assessment of Quassinoids Neosergeolide and Isobrucein B toward Hematopoietic and Solid Malignancies Identifies STAT3 Activation To Be Predictive of Antitumor Response.
Authors: Mitsuteru Hiwatari, Jingqiu Dai, Wei Liu, Yu-Dong Zhou, Dale G. Nagle, Stephan W. Morris
Journal: Blood (2007)
Effects of Subsidies and Prohibitions on Nutrition in a Food Benefit Program
Authors: Lisa Harnack, J. Michael Oakes, Brian Elbel, Timothy Beatty, Sarah Rydell, Simone French
Journal: JAMA Internal Medicine (2016)

<h3>Importance</h3> Strategies to improve the nutritional status of those participating in the Supplemental Nutrition Assistance Program (SNAP) are of interest to policymakers. <h3>Objective</h3> To evaluate whether the proposed policy of incentivizing the purchase of fruits and vegetables and prohibiting the purchase of less nutritious foods in a food benefit program improves the nutritional quality of participants’ diets. <h3>Design, Setting, and Participants</h3> Lower income participants (n = 279) not currently enrolled in SNAP were randomized to 1 of 4 experimental financial food benefit conditions: (1) incentive (30% financial incentive for fruits and vegetables purchased using food benefits); (2) restriction (not allowed to buy sugar sweetened beverages, sweet baked goods, or candies with food benefits); (3) incentive plus restriction (30% financial incentive on fruits and vegetables and restriction of purchase of sugar sweetened beverages, sweet baked goods, or candy with food benefits); or (4) control (no incentive or restrictions on foods purchased with food benefits). Participants in all conditions were given a study-specific debit card where funds were added every 4 weeks for a 12-week period. Outcome measures were collected at baseline and in the final 4 weeks of the experimental period. <h3>Main Outcomes and Measures</h3> Primary outcomes (from 24-hour dietary recalls) included intake of energy, discretionary calories, and overall diet quality. <h3>Results</h3> A number of favorable changes were observed in the incentive plus restriction condition that were significantly different from changes in the control condition. These included (1) reduced intake of energy (−96 kcal/d, standard error [SE], 59.9); (2) reduced intake of discretionary calories (−64 kcal/d, SE 26.3); (3) reduced intake of sugar sweetened beverages, sweet baked goods, and candies (−0.6 servings/d, SE 0.2); (4) increased intake of solid fruit (0.2 servings/d, SE 0.1); and (5) improved Healthy Eating Index score (4.1 points, SE 1.4). Fewer improvements were observed in the incentive only and restriction only arms. <h3>Conclusions and Relevance</h3> A food benefit program that pairs incentives for purchasing more fruits and vegetables with restrictions on the purchase of less nutritious foods may reduce energy intake and improve the nutritional quality of the diet of participants compared with a program that does not include incentives or restrictions. <h3>Clinical Trial Registration</h3> clinicaltrials.gov Identifier:NCT02643576
ADDITION OF EBUS-MAPPING OF THE MEDIASTINUM TO PET/CT BASED SELECTIVE NODAL IRRADIATION IN NSCLC DECREASES GEOGRAPHICAL MISS AND NODAL GTV VOLUME
Authors: Stéphanie Peeters, Christophe Dooms, Johan Vansteenkiste, Herbert Decaluwé, Paul De Leyn, Kristiaan Nackaerts, Walter De Wever, Christophe Deroose, Dirk De Ruysscher
Journal: Journal of Thoracic Oncology (2013)
Effect of Fibrate-Add-On Treatment in Primary Biliary Cholangitis Patients with an Insufficient Response to Ursodeoxycholic Acid
Authors: C. Freissmuth, K. Kozbial, A.F. Stättermayer, S. Beinhardt, R. Stern, E. Halilbasic, P. Ferenci, M. Trauner, H. Hofer
Journal: Journal of Hepatology (2016)
Circulating lymphoma cells in intravascular large B‐cell lymphoma
Authors: Nicholas J. Fordham, Simon O'Connor, Simon Stern, Veselka Nikolova, Barbara J. Bain
Journal: American Journal of Hematology (2016)

A 92-year-old Caucasian man who was dialysis dependent due to autosomal dominant polycystic kidney disease presented with thrombocytopenia and weight loss. On examination, his spleen was palpable 6 cm below the left costal margin but there was no palpable lymphadenopathy. His blood count showed a stable hemoglobin concentration of 101 g/l but a markedly reduced platelet count of 44 × 109/l and a white cell count of 19.3 × 109/l. An automated differential count suggested that there was monocytosis and lymphocytosis but a blood film showed that the abnormal cells were all lymphoid, with the count being neutrophils 3.8 × 109/l, lymphoid cells 12 × 109/l, monocytes 0.6 × 109/l, and eosinophils 0.1× 109/l. The abnormal cells were medium to large with a high nucleocytoplasmic ratio, a single large but indistinct nucleolus and moderately basophilic cytoplasm (top left). Flow cytometric immunophenotyping on peripheral blood showed the abnormal cells to be large B cells expressing CD19, CD20, CD79b, and BCL2 with kappa light chain restriction. They were negative for CD5, CD10, CD23, CD43, and CD200. The proliferation fraction (Ki-67 positive) was 67%. A bone marrow aspirate was hemodilute, with some maturing hematopoietic cells but also lymphoid cells similar to those seen in the peripheral blood. Trephine biopsy sections were hypercellular for the patient's advanced age and showed atypical medium to large cells, with prominent nucleoli, within sinusoids and capillaries (top right, hematoxylin and eosin, ×40 objective). Immunohistochemistry for CD20 (bottom left) confirmed that the abnormal cells were largely intravascular with smaller numbers of single cells and small aggregates in the interstitium. The neoplastic cells also expressed CD19 and CD79a while CD10, MUM1/IRF4, and EBER were negative. CD34 staining of endothelial cells confirmed their intravascular location (bottom right). The patient was given a trial of high dose corticosteroids but died shortly afterward. The prognosis of intravascular large B-cell lymphoma is usually adverse, at least in part due to the difficulty in making the diagnosis. In our patient, the unusual presence of circulating cells led to examination of the bone marrow. Despite the speedy diagnosis, treatment in this elderly dialysis-dependent man was unsuccessful.
Improved Recovery After Laparoscopic Bilateral Inguinal Hernia Repair
Authors: Robert V. Rege
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Clinical Characteristics of Intrahepatic Cholangiocarcinoma in Spain. Liver Cirrhosis and High AFP are not Always Hepatocellular Carcinoma
Authors: C. Rodriguez-Lope, M. Forne, J. Fuentes, M. Reig, V. Andreu, B. Minguez, M. Iñarrairaegui, C. Fernández, M. Roget, A. Lue, I. Ortiz, F. Jimenez, S. Montoliu, M.C. Garre, P. Rendon, M. Rodríguez, J. Crespo, J. Bruix, M. Varela
Journal: Journal of Hepatology (2016)
The metamorphosis of medical ethics. A 30-year retrospective
Authors: E. D. Pellegrino
Journal: JAMA (1993)

History is philosophy teaching by example. Dionysius of Halicarnassus When I entered medical school 50 years ago, medical ethics was, as it had been for centuries, solely the domain of the profession, protected from the mainstream of cultural change and framed in seemingly immutable moral precepts. This is the way medical ethics also appeared 30 years ago when I began to study, teach, and observe the field. If there was anything that seemed impervious to the metamorphosis we felt all of medicine to be undergoing, it was its ancient ethical framework. Today, that framework is under the severest strain in its long history. Medical ethics has become a subject of the widest public concern. Every one of its tenets is being seriously questioned and is likely to be reformulated. Under pressure of moral conflicts buffeting our entire culture, traditional moral supports have been weakened and precepts disassembled. Just what medical
CC-31244, A Novel, Pan-Genotypic, Potent NS5B Non-Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C
Authors: I. Jacobson, M. Feese, H. Xiao, L. Uher, B. Lin, E. Sanchez, R. Tomkiewicz, T. Whitaker, T. McBrayer, L. Pascual, J. Pattassery, S. Lee
Journal: Journal of Hepatology (2016)
The Relationship between FIB-4 Index Variations and Outcome in Patients with Chronic Hepatitis C and Cirrhosis: Comparison with Liver Stiffness Measurement
Authors: A. Vallet-Pichard, P. Sultanik, J.F. Meritet, S. Bouam, H. Fontaine, M. Corouge, A. Laurain, P. Sogni, S. Pol, V. Mallet
Journal: Journal of Hepatology (2016)
The Macrophage Protein CD5L Acts as a Pro-Oncogenic Factor in Hepatocytes
Authors: G. Aran, L. Sanjurjo, C. Bárcena, M. Javid, M. Simon, M. Vázquez, E. Díaz, C. Huertas, M. Varela, M. Miquel, S. Coll, I. Ojanguren, R. Bartolí, M. Sala, R. Planas, C. Armengol, M.-R. Sarrias
Journal: Journal of Hepatology (2016)
Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States
Authors: Krishna G. Aragam, Dadi Dai, Megan L. Neely, Deepak L. Bhatt, Matthew T. Roe, John S. Rumsfeld, Hitinder S. Gurm
Journal: Journal of the American College of Cardiology (2015)
Five-Year Outcome of Telbivudine versus Entecavir in Treating High Viral Load Chronic Hepatitis B Patients
Authors: H.-Y. Pan, Z.-Z. Ren, H.-J. Huang, H. Zou, Y.-X. Tong, D.-H. Yang, H.-Y. Pan, M.-J. Chen, M.-S. Wang, Y.-C. Huang, J.-J. Zhang
Journal: Journal of Hepatology (2016)